Loading...

Vaccine Development and Manufacturing

ISBN: 978-0-470-26194-1

November 2014

456 pages

Description

Invaluable reference on how to produce a vaccine—from beginning to end

Vaccine production is a major unit of many pharmaceutical companies. With several biotechnology companies involved in developing new types of vaccines, tremendous advances are been observed continually in all aspects of vaccine manufacturing. Novel adjuvants discovered in recent years have shown great promises in human clinical trials by helping elicit stronger immune response and provide durable memory effects. New concepts in facility designs have enabled multiple use of the same facility. Vaccine Development and Manufacturing serves as a reference on all aspects of vaccine production by providing an in-depth description of the available technologies for making different types of vaccines and the current thinking in facility designs and supply issues.

Vaccine Development and Manufacturing comprehensively covers a wide range of issues from the following:

  • Process perspective—fermentation to purification to formulation developments
  • Production—facility design to manufacturing
  • Regulatory perspective—requirements from government agencies
  • Challenges and issues involved in manufacturing different types of vaccines

With contributions by authors from various major pharmaceutical and biotechnology companies, this book will be a resource for a plethora of experts, including R&D scientists, medical professionals, regulatory specialists, clinical researchers, manufacturing specialists, and quality-related personnel. This book will provide insights to the issues that scientists face and the steps involved in producing a vaccine, and will be a reference for state-of-the-art vaccine manufacturing technologies and facility setup.

About the Author

EMILY P. WEN, PhD, is currently a Research Fellow at the Merck Research Laboratory in the department of Vaccine Process Development. Dr. Wen has led process developments for several major vaccine products from Phase I to Phase III clinical trials, including vaccines against hepatitis B, Haemophilus influenzae type b, Pneumococcal, Meningococcal, and Group B Streptococcus.

RONALD ELLIS, PhD, is Chief Technology Officer at FutuRx Ltd in Israel. Dr. Ellis has more than 30 years of industry experience in line and senior management in many companies, including roles as project leader and champion of projects that resulted in five licensed vaccines which accrue ~$4B in annual sales. He is the founding and incumbent Editor-in-Chief of the MedLine-/PubMed-indexed journal Human Vaccines & Immunotherapeutics.

NARAHARI S. PUJAR, PhD, MBA, is currently an Executive Director and Integrated Product Leader in the Vaccine Business Line at Merck & Co., Inc. Dr. Pujar has contributed to a variety of vaccines and biologics products and product candidates. He is an active member of the American Chemical Society and was the past chair of the Division of Biochemical Technology.